GV1001 was the first TERT peptide vaccine to be evaluated for treating advanced pancreatic cancer, lung carcinoma, melanoma, and liver carcinoma in clinical trials [261,262,263,264,265,266,267,268]. This evidence concerns the gene TERT and melanoma.